Listeriosis in patients receiving biologic therapies

摘要: The evolution of inflammatory diseases has radically changed since the introduction biologic therapies, such as tumour necrosis factor alpha inhibitors (anti-TNFα). They, therefore, represent a widely used therapeutic modality. Nevertheless, post-marketing studies reveal an increased risk infection in patients taking these drugs, especially granulomatous infections listeriosis. We aimed to evaluate reported cases listeriosis treated with treatments. United States Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) from 2004 2011. also perform literature review previously therapies. identified 266 Listeria monocytogenes associated majority were receiving infliximab (77.1 %), followed by etanercept (11.7 adalimumab (9.8 rituximab (4.1 abatacept (0.4 %) golimumab %). Indications for use biologics follows: 47.7 % rheumatologic diseases, 38 bowel 3.4 haematological 10.5 other indications. Seventy-three percent concomitant immunosuppressant steroids (56 methotrexate (31.6 median time onset was 184 days. Mortality rates range 11.1 adalimumab-treated 27.3 rituximab-treated (p = 0.7). Listeriosis is common biologics-treated patients, related given concomitantly immunosuppressive Infections after treatment mostly occurred first year initiating treatment.